Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes.

[1]  K. Floyd,et al.  25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward , 2022, The Lancet Infectious Diseases.

[2]  B. Meibohm,et al.  Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis. , 2021, ACS infectious diseases.

[3]  B. Meibohm,et al.  Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis , 2021, Antimicrobial agents and chemotherapy.

[4]  M. Gutierrez,et al.  Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide , 2021, Nature Communications.

[5]  H. Bax,et al.  Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model , 2021, Antimicrobial Agents and Chemotherapy.

[6]  B. Aldridge,et al.  Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis , 2021, bioRxiv.

[7]  R. Agrawal,et al.  Replacement of S14 Protein in Ribosomes of Zinc-Starved Mycobacteria Reduces Spectinamide Sensitivity , 2020, Antimicrobial Agents and Chemotherapy.

[8]  V. Dartois,et al.  Caseum: a Niche for Mycobacterium tuberculosis Drug-Tolerant Persisters , 2020, Clinical Microbiology Reviews.

[9]  R. B. Abramovitch,et al.  Acid Fasting: Modulation of Mycobacterium tuberculosis Metabolism at Acidic pH. , 2019, Trends in microbiology.

[10]  B. Meibohm,et al.  Dynamic time‐kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  B. Meibohm,et al.  Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice. , 2019, Tuberculosis.

[12]  Jonathan A. G. Cox,et al.  Modelling a Silent Epidemic: A Review of the In Vitro Models of Latent Tuberculosis , 2018, Pathogens.

[13]  M. Neely,et al.  Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model , 2018, Antimicrobial Agents and Chemotherapy.

[14]  B. Meibohm,et al.  Structure-Activity Relationships of Spectinamide Antituberculosis Agents: A Dissection of Ribosomal Inhibition and Native Efflux Avoidance Contributions. , 2017, ACS infectious diseases.

[15]  G. Robertson,et al.  Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models , 2016, The Journal of antimicrobial chemotherapy.

[16]  J. J. Cadwell,et al.  The hollow fiber infection model for antimicrobial pharmacodynamics and pharmacokinetics , 2017 .

[17]  C. Nathan,et al.  Targeting Phenotypically Tolerant Mycobacterium tuberculosis , 2017, Microbiology spectrum.

[18]  B. Meibohm,et al.  Translational PK/PD of anti-infective therapeutics. , 2016, Drug discovery today. Technologies.

[19]  Ulrika S H Simonsson,et al.  A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro , 2015, The Journal of antimicrobial chemotherapy.

[20]  B. Meibohm,et al.  In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics , 2015, Scientific Reports.

[21]  B. Meibohm,et al.  Spectinamides: A New Class of Semisynthetic Anti-Tuberculosis Agents that Overcome Native Drug Efflux , 2014, Nature Medicine.

[22]  A. Golas,et al.  Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model. , 2013, ACS chemical biology.

[23]  Ronald N. Jones,et al.  Relationship between Ceftolozane-Tazobactam Exposure and Drug Resistance Amplification in a Hollow-Fiber Infection Model , 2013, Antimicrobial Agents and Chemotherapy.

[24]  Y. Av‐Gay,et al.  Mycobacterium tuberculosis modulators of the macrophage's cellular events. , 2012, Microbes and infection.

[25]  Diogo F. Veiga,et al.  Linking the Transcriptional Profiles and the Physiological States of Mycobacterium tuberculosis during an Extended Intracellular Infection , 2012, PLoS pathogens.

[26]  T. Kirikae,et al.  A Novel Mechanism of Growth Phase-dependent Tolerance to Isoniazid in Mycobacteria* , 2012, The Journal of Biological Chemistry.

[27]  S. Kaufmann,et al.  Mycobacterium tuberculosis: success through dormancy. , 2012, FEMS microbiology reviews.

[28]  M. Barer,et al.  Targeting Persisters for Tuberculosis Control , 2012, Antimicrobial Agents and Chemotherapy.

[29]  A. Ginsberg.  Drugs in Development for Tuberculosis , 2010, Drugs.

[30]  G. Drusano,et al.  Effect of Administration of Moxifloxacin plus Rifampin against Mycobacterium tuberculosis for 7 of 7 Days versus 5 of 7 Days in an In Vitro Pharmacodynamic System , 2011, mBio.

[31]  S. Jhamb,et al.  Models of Latent Tuberculosis: Their Salient Features, Limitations, and Development , 2011, Journal of laboratory physicians.

[32]  Fong-Fu Hsu,et al.  aprABC: a Mycobacterium tuberculosis complex‐specific locus that modulates pH‐driven adaptation to the macrophage phagosome , 2011, Molecular microbiology.

[33]  S. Morris,et al.  Sensitivity to Isoniazid of Mycobacterium bovis BCG Strains and BCG Disseminated Disease Isolates , 2011, Journal of Clinical Microbiology.

[34]  R. Roy,et al.  Correction: Anchor-Based Whole Genome Phylogeny (ABWGP): A Tool for Inferring Evolutionary Relationship among Closely Related Microorganisms , 2010, PLoS ONE.

[35]  S. Waddell,et al.  Examining the basis of isoniazid tolerance in nonreplicating Mycobacterium tuberculosis using transcriptional profiling. , 2010, Future medicinal chemistry.

[36]  G. Drusano,et al.  The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model , 2010, mBio.

[37]  B. Meibohm,et al.  A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. , 2009, Tuberculosis.

[38]  T. Gumbo,et al.  Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs , 2009, Antimicrobial Agents and Chemotherapy.

[39]  T. Ottenhoff,et al.  Lack of Immune Responses to Mycobacterium tuberculosis DosR Regulon Proteins following Mycobacterium bovis BCG Vaccination , 2007, Infection and Immunity.

[40]  G. Drusano,et al.  Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. , 2007, The Journal of infectious diseases.

[41]  Maria L. Gennaro,et al.  Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. McFadden,et al.  Compiling a Molecular Inventory for Mycobacterium bovis BCG at Two Growth Rates: Evidence for Growth Rate-Mediated Regulation of Ribosome Biosynthesis and Lipid Metabolism , 2005, Journal of bacteriology.

[43]  P. Venkatesan,et al.  Bactericidal Action of Gatifloxacin, Rifampin, and Isoniazid on Logarithmic- and Stationary-Phase Cultures of Mycobacterium tuberculosis , 2005, Antimicrobial Agents and Chemotherapy.

[44]  Hartmut Derendorf,et al.  Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives , 1999, Pharmaceutical Research.

[45]  Julian Parkhill,et al.  The complete genome sequence of Mycobacterium bovis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Thomas Dick,et al.  Mycobacterium bovis BCG Response Regulator Essential for Hypoxic Dormancy , 2002, Journal of bacteriology.

[47]  J. Betts,et al.  Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling , 2002, Molecular microbiology.

[48]  N Rastogi,et al.  Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. , 2000, The Journal of antimicrobial chemotherapy.

[49]  P. Venkatesan,et al.  Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis , 1996, Antimicrobial agents and chemotherapy.

[50]  L. Wayne,et al.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence , 1996, Infection and immunity.

[51]  L. Wayne,et al.  Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis , 1994, Antimicrobial Agents and Chemotherapy.

[52]  K. Wilson,et al.  Extensive DNA sequence conservation throughout the Mycobacterium tuberculosis complex , 1994, Journal of clinical microbiology.

[53]  D. Cohn,et al.  A 62-Dose, 6-Month Therapy for Pulmonary and Extrapulmonary Tuberculosis: A Twice-Weekly, Directly Observed, and Cost-Effective Regimen , 1990 .

[54]  K. Hong.  Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis second reportthe results up to 24 months , 1982 .

[55]  J. A. Barbaro,et al.  Tuberculous chemotherapy for recalcitrant outpatients administered directly twice weekly. , 1968, The American review of respiratory disease.